Moderna, Inc. (NASDAQ:MRNA) shares are up nearly 5% on Tuesday after the company announced positive preliminary immunogenicity data for its 2025-2026 Spikevax formula, which targets the new LP.8.1 variant of COVID-19.
CrowdStrike is little changed after unveiling NVIDIA integrations and a deal to buy Pangea to expand Falcon into full AI detection-and-response; shares up ~0.3%.